SCHEMBL2485333

SCHEMBL2485333

COc1ccc(Cn2ncc3c4c(cnc32)CN(C(=S)Nc2ccccc2)CC4)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 4/20 0.48
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
ALOX15 P16050 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RYR2 Q92736 1/20 0.45
CDK1 P06493 2/20 0.44
IGF1R P08069 2/20 0.44
FGFR1 P11362 2/20 0.44
BRAF P15056 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488683 0.91 FAAH (0.52) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2489970 0.83 KMT2A (0.48) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2488863 0.83 ALDH1A1 (0.43) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2485402 0.82 NPC1 (0.45) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2486745 0.82 ALDH1A1 (0.42) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2489943 0.81 ADORA1 (0.46) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2802902 0.81 ADORA1 (0.44) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2805078 0.80 ADORA1 (0.44) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL12315714 0.79 ALDH1A1 (0.48) HPGDSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL2489846 0.79 ABCB1 (0.47) HPGDSMN1; SMN2ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
EP-2379551-A1 SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 EP disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HPGD 87/4885SMN1; SMN2 1523/4885ALDH1A1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.